The Australia & New Zealand healthcare CROs market size is expected to reach USD 2.4 billion by 2030. The market is expected to expand at a CAGR of 11.5% from 2023 to 2030. The rising costs associated with drug development are anticipated to drive the demand. As clinical trial costs continue to increase and challenges related to patient recruitment persist, biopharmaceutical companies are increasingly turning to countries such as Australia, New Zealand, China, and India in search of cost savings and efficient patient recruitment. As a result, the market is expected to benefit from this trend over the forecast period.
R&D tax credits are available in both countries. According to the April 2021 update from Brandon Capital Partners, a key Australasian life sciences venture capital firm, the R&D tax incentive given to international sponsors in Australia can lead to savings in costs of up to 43.5%, in comparison to New Zealand's 15%. In addition, the article stated that the Australian government projected that its tax credit helped the clinical trial sector reach a value of USD 1 billion, which would eventually boost the Australia and New Zealand contract research organizations industry’s growth.
The growing adoption of digital health technologies, such as telemedicine, wearables, and AI, is impacting drug development & clinical trials, creating new opportunities for contract research organizations. Australia is one of the leading countries to conduct decentralized clinical trials; according to Novotech, During the COVID-19 pandemic, Australia demonstrated significant progress in online care platforms. From March 2020 to April 2021, more than 56 million telehealth services were provided to around 13.6 million patients. In addition, the government's recent 2021-2022 Federal Budget allocated an additional USD 204.6 million to telehealth, bringing the total investment to USD 3.6 billion.
R&D tax credits are available in both countries. According to the April 2021 update from Brandon Capital Partners, a key Australasian life sciences venture capital firm, the R&D tax incentive given to international sponsors in Australia can lead to savings in costs of up to 43.5%, in comparison to New Zealand's 15%. In addition, the article stated that the Australian government projected that its tax credit helped the clinical trial sector reach a value of USD 1 billion, which would eventually boost the Australia and New Zealand contract research organizations industry’s growth.
The growing adoption of digital health technologies, such as telemedicine, wearables, and AI, is impacting drug development & clinical trials, creating new opportunities for contract research organizations. Australia is one of the leading countries to conduct decentralized clinical trials; according to Novotech, During the COVID-19 pandemic, Australia demonstrated significant progress in online care platforms. From March 2020 to April 2021, more than 56 million telehealth services were provided to around 13.6 million patients. In addition, the government's recent 2021-2022 Federal Budget allocated an additional USD 204.6 million to telehealth, bringing the total investment to USD 3.6 billion.
Australia & New Zealand Healthcare CROs Market Report Highlights
- Based on phase type, the clinical segment dominated the market in 2022, with the largest share of 76.4%, because it comprises four elaborate phases, including human subjects. The significant demand for new treatments has further contributed to the growth of the segment
- The regulatory/medical affairs service segment is expected to register the fastest CAGR of 15.6% over the forecast period
- The oncology application segment accounted for the largest market share of 40.2% owing to the increasing incidence of cancer, advancements in oncology research, and the growing demand for targeted therapies
- Pharmaceutical & Biopharmaceutical companies by end-use segment is expected to register the fastest CAGR of 11.7% over the forecasted period
Table of Contents
Chapter 1 Research Methodology & Scope1.1 Market Segmentation and Scope
1.2 Market Definitions
1.2.1 Phase Type
1.2.2 Service
1.2.3 Application
1.2.4 End Use
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Information analysis
1.4.2 Market formulation & data visualization
1.4.3 Data validation & publishing
1.5 Research Scope and Assumptions
1.5.1 Commodity Flow Analysis
1.5.2 Top-down market estimation
1.5.3 Country-based segment share calculation
1.5.4 Multivariate analysis
1.5.5 Australia and New Zealand Healthcare CROs market: CAGR Calculation
1.6 List of Secondary Sources
1.7 List of Abbreviations
1.8 Objectives
1.8.1 Objective - 1:
1.8.2 Objective - 2:
1.8.3 Objective - 3:
1.8.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.2.1 Segment snapshot (Phase type & application)
2.2.2 Segment snapshot (Service)
2.2.3 Segment snapshot (End-use)
2.3 Competitive Landscape Snapshot
Chapter 3 Australia & New Zealand Healthcare Contract Research Organizations Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.1.2 Ancillary Market Outlook
3.2 Market Driver Analysis
3.2.1 Market Driver IMPACT Analysis
3.2.1.1 Increasing adoption of advanced technologies
3.2.1.2 Rising strategic Competitive initiatives
3.2.1.2.1 Geographical expansion
3.2.1.2.2 Mergers and Acquisitions
3.2.1.3 R&D Grants and Tax Incentives
3.2.1.4 Cost-Effectiveness & Favorable environment for clinical trials
3.2.2 Market Restraint Impact Analysis
3.2.2.1 Quality Concerns in CRO services
3.2.2.2 Intellectual property rights issues
3.3 Industry Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis
3.4 Impact & Reformation By Covid-19
3.4.1 Overall COVID-19 Impact
3.4.2 COVID-19 impact on notable global market players that OPERATE in Australian and New Zealand Healthcare CROs Market
3.4.2.1 IQVIA
3.4.2.2 SYNEOS HEALTH
3.4.2.3 ICON PLC
3.4.2.4 LABCORP
3.4.2.5 PPD (Thermo Fisher Scientific Inc.)
3.4.2.6 CHARLES RIVER Laboratories
3.4.3 PostCOVID-19 Impact on the Market
Chapter 4 Australia & New Zealand Healthcare CRO Market: Phase Type Segment Analysis
4.1 Australia & New Zealand Healthcare CRO: Market Share Analysis, 2022 & 2030
4.2 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Phase Type, 2018 - 2030 (USD Million)
4.3 Drug Discovery
4.3.1 Target validation
4.3.2 Lead identification
4.3.3 Lead optimization
4.4 Preclinical
4.5 Clinical
4.5.1 Phase I Trial Services
4.5.2 Phase II Trial Services
4.5.3 Phase III Trial Services
4.5.4 Phase IV Trial Services
Chapter 5 Australia & New Zealand Healthcare CRO Market: Service Segment Analysis
5.1 Australia & New Zealand Healthcare CRO: Market Share Analysis, 2022 & 2030
5.2 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Services, 2018 - 2030 (USD Million)
5.3 Project Management/Clinical Supply Management
5.4 Data Management
5.5 Regulatory/Medical Affairs
5.6 Medical Writing
5.7 Clinical Monitoring
5.8 Quality Management/ Assurance
5.9 Bio-statistics
5.10 Investigator Payments
5.11 Laboratory
5.12 Patient and Site Recruitment
5.13 Technology Services
5.14 Other Services
Chapter 6 Australia & New Zealand Healthcare CRO Market: Application Segment Analysis
6.1 Australia & New Zealand Healthcare CRO: Market Share Analysis, 2022 & 2030
6.2 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Application, 2018 - 2030 (USD Million)
6.3 Oncology
6.4 Cardiovascular
6.5 Autoimmune/Inflammation
6.6 Central Nervous System (CNS)
6.7 Dermatology
6.8 Infectious Diseases
6.9 Respiratory
6.10 Others
Chapter 7 Australia & New Zealand Healthcare CRO Market: End-use Segment Analysis
7.1 Australia & New Zealand Healthcare CRO: Market Share Analysis, 2022 & 2030
7.2 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by End-use, 2018 - 2030 (USD Million)
7.3 Pharmaceutical & Biopharmaceutical Companies
7.4 Medical Device Companies
Chapter 8 Australia & New Zealand Healthcare CRO Market: Country Analysis
8.1 AUSTRALIA
8.1.1 Key Country Dynamics
8.1.2 Competitive Scenario
8.1.3 Regulatory Framework
8.1.3.1 Australia Healthcare CRO MARKET estimates and forecasts, 2018 - 2030 (USD Million)
8.2 New Zealand
8.2.1 Key Country Dynamics
8.2.2 Competitive Scenario
8.2.3 Regulatory Framework
8.2.3.1 New Zealand Healthcare CRO MARKET estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9 Australia & New Zealand Healthcare CRO Market: Competitive Landscape
9.1 Company Profile
9.1.1 Paraxel International Corporation
9.1.1.1 Company Overview
9.1.1.2 Financial Performance
9.1.1.3 Service Benchmarking
9.1.1.4 Strategic Initiatives
9.1.2 SGS SA
9.1.2.1 Company Overview
9.1.2.2 Financial Performance
9.1.2.3 Service Benchmarking
9.1.2.4 Strategic Initiatives
9.1.3 ICON plc
9.1.3.1 Company Overview
9.1.3.2 Financial Performance
9.1.3.3 Service Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4 Thermo Fisher Scientific Inc. (PPD)
9.1.4.1 Company Overview
9.1.4.2 Financial Performance
9.1.4.3 Service Benchmarking
9.1.4.4 Strategic Initiatives
9.1.5 Medpace Australia Pty. Ltd
9.1.5.1 Company Overview
9.1.5.2 Financial Performance
9.1.5.3 Service Benchmarking
9.1.5.4 Strategic Initiatives
9.1.6 Charles River Laboratories International, Inc.
9.1.6.1 Company Overview
9.1.6.2 Financial Performance
9.1.6.3 Service Benchmarking
9.1.6.4 Strategic Initiatives
9.1.7 IQVIA
9.1.7.1 Company Overview
9.1.7.2 Financial Performance
9.1.7.3 Service Benchmarking
9.1.7.4 Strategic Initiatives
9.1.8 Novotech
9.1.8.1 Company Overview
9.1.8.2 Financial Performance
9.1.8.3 Service Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9 Laboratory Corporation of America Holdings
9.1.9.1 Company Overview
9.1.9.2 Financial Performance
9.1.9.3 Service Benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 Syneos Health
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Service Benchmarking
9.1.10.4 Strategic Initiatives
9.2 Company Heat Map Analysis
9.3 Strategy Mapping
9.3.1 Expansion
9.3.2 Mergers & acquisition
9.3.3 Collaborations
9.3.4 Partnership
9.3.5 Others
List of Tables
Table 1 Phase type segment definition
Table 2 Service segment definition
Table 3 Application segment definition
Table 4 End use segment definition
Table 5 List of secondary sources
Table 6 List of abbreviations
Table 7 Strategic collaborations by key players
Table 8 Strategic partnerships with biopharmaceutical companies
Table 9 Major acquisitions in the global CRO market in 2020 - 2021
Table 10 Australia notable grants and incentives for R&D activities
Table 11 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Type, 2018 - 2030 (USD Million)
Table 12 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Type, 2018 - 2030 (USD Million)
Table 13 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Clinical, 2018 - 2030 (USD Million)
Table 14 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Type, 2018 - 2030 (USD Million)
Table 15 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by Application, 2018 - 2030 (USD Million)
Table 16 Australia and New Zealand Healthcare Contract Research Outsourcing Market, by end-use, 2018 - 2030 (USD Million)
Table 17 Clinical trial application requirements in Australia, U.S., and the EU
Table 18 Main documents required for regulatory and ethics committee submissions
List of Figures
Fig. 1 Australia and New Zealand Healthcare CRO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Data Analysis Models
Fig. 5 Market Formulation And Validation
Fig. 6 Data Validating & Publishing
Fig. 7 Commodity flow analysis
Fig. 8 Segment snapshot (Phase type & application)
Fig. 9 Segment snapshot (Service)
Fig. 10 Segment snapshot ( End-use)
Fig. 11 Healthcare Contract Research Outsourcing Market Value, 2022 (USD Million)
Fig. 12 Ancillary Market Value, 2022 (USD Million)
Fig. 13 Market trends and outlook
Fig. 14 Total number of merger & acquisition deals and buyouts across global CROs & CDMOs (2016 - 2020)
Fig. 15 Porter’s five forces analysis
Fig. 16 PEST Analysis
Fig. 17 Australia & New Zealand Healthcare CRO market phase type outlook: Segment dashboard
Fig. 18 Australia & New Zealand Healthcare CRO market: type movement analysis
Fig. 19 Drug discovery market, 2018 - 2030 (USD Million)
Fig. 20 Target validation market, 2018 - 2030 (USD Million)
Fig. 21 Lead identification market, 2018 - 2030 (USD Million)
Fig. 22 Lead optimization market, 2018 - 2030 (USD Million)
Fig. 23 Preclinical market, 2018 - 2030 (USD Million)
Fig. 24 Clinical market, 2018 - 2030 (USD Million)
Fig. 25 Phase I trial services market, 2018 - 2030 (USD Million)
Fig. 26 Phase II trial services market, 2018 - 2030 (USD Million)
Fig. 27 Phase III trial services market, 2018 - 2030 (USD Million)
Fig. 28 Phase IV trial services market, 2018 - 2030 (USD Million)
Fig. 29 Australia & New Zealand Healthcare CRO market service outlook: Segment dashboard
Fig. 30 Australia & New Zealand Healthcare CRO market: Service movement analysis
Fig. 31 Project management/clinical supply management market, 2018 - 2030 (USD Million)
Fig. 32 Parameters for measuring the success of provider solution
Fig. 33 Data management market, 2018 - 2030 (USD Million)
Fig. 34 Clinical data management flow
Fig. 35 Regulatory/medical affairs market, 2018 - 2030 (USD Million)
Fig. 36 Medical writing market, 2018 - 2030 (USD Million)
Fig. 37 Clinical monitoring market, 2018 - 2030 (USD Million)
Fig. 38 Quality management/ assurance market, 2018 - 2030 (USD Million)
Fig. 39 Bio-statistics market, 2018 - 2030 (USD Million)
Fig. 40 Investigator payments market, 2018 - 2030 (USD Million)
Fig. 41 Laboratory market, 2018 - 2030 (USD Million)
Fig. 42 Patient and site recruitment market, 2018 - 2030 (USD Million)
Fig. 43 Strategic initiatives with a positive impact on patient recruitment
Fig. 44 Technology services market, 2018 - 2030 (USD Million)
Fig. 45 Other services market, 2018 - 2030 (USD Million)
Fig. 46 Australia & New Zealand Healthcare CRO market application outlook: Segment dashboard
Fig. 47 Australia & New Zealand Healthcare CRO market: application movement analysis
Fig. 48 Oncology market, 2018 - 2030 (USD Million)
Fig. 49 Cardiovascular market, 2018 - 2030 (USD Million)
Fig. 50 Autoimmune/Inflammation market, 2018 - 2030 (USD Million)
Fig. 51 Central nervous system (CNS) market, 2018 - 2030 (USD Million)
Fig. 52 Dermatology market, 2018 - 2030 (USD Million)
Fig. 53 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 54 Respiratory market, 2018 - 2030 (USD Million)
Fig. 55 Others market, 2018 - 2030 (USD Million)
Fig. 56 Australia & New Zealand Healthcare CRO market end-use outlook: Segment dashboard
Fig. 57 Australia & New Zealand Healthcare CRO market: end-use movement analysis
Fig. 58 Pharmaceutical & biopharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 59 Medical device companies market, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Site start-up timelines (public and private sites) in Australia (CTN scheme)
Fig. 62 Timeline estimates for FIH trial completion in Australia compared to Europe and North America
Fig. 63 Australia healthcare CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Clinical trial approval procedure in NZ
Fig. 66 New Zealand healthcare CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Strategic framework
Companies Mentioned
- Paraxel International Corporation
- SGS SA
- ICON plc
- Thermo Fisher Scientific Inc. (PPD)
- Medpace Australia Pty. Ltd
- Charles River Laboratories International, Inc.
- IQVIA
- Novotech
- Laboratory Corporation of America Holdings
- Syneos Health
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 122 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1 Billion |
| Forecasted Market Value ( USD | $ 2.4 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Australia, New Zealand |
| No. of Companies Mentioned | 10 |
